Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996806 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL7978226 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL9359626 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL1814002 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL10795076 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL24866537 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL9587111 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL21148 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL10348708 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL436440 | 1.00 | CYP2D6 (0.52) | CYP2D6LMNABLMALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044010-B1 | NEW PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INIHIBITORS AND THE USE THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDO RESZVENYTARSASAG (HU) | 2014-01-08 | — | — | EP | claimed |
| US-20100286404-A1 | PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-11-11 | — | — | US | claimed |
| US-20100143981-A1 | WHOLE-CELL CATALYTIC SYSTEM COMPRISING A HYDANTOINASE, A RACEMASE AND A CARBAMOYLASE | DSM IP ASSETS B.V. (NL) | 2010-06-10 | — | — | US | claimed |
| EP-2102353-A2 | WHOLE-CELL CATALYTIC SYSTEM COMPRISING A HYDANTOINASE, A RACEMASE AND A CARBAMOYLASE | DSM IP Assets B.V. (NL) | 2009-09-23 | — | — | EP | claimed |
| WO-2008067981-A2 | WHOLE-CELL CATALYTIC SYSTEM COMPRISING A HYDANTOINASE, A RACEMASE AND A CARBAMOYLASE | DSM IP ASSETS B.V. (NL) | 2008-06-12 | — | — | WO | claimed |
| US-6541635-B1 | Silylprotected L-proline derivative or salt is deprotected in presence of a nonaqueous medium containing an organic solvent at a temperature of 5 degree C. to 40 degree C. | EVERLIGHT USA, INC. | 2003-04-01 | — | — | US | claimed |
| EP-0344572-A2 | Composition of angiotensin-converting-enzyme inhibitor with calcium chanell modulators and uses thereof as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-12-06 | — | — | EP | claimed |
| EP-0338508-A2 | Esters from amino-acids, their preparation process, drugs containing same and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-10-25 | — | — | EP | claimed |
| EP-0278158-A2 | Renin inhibitors containing phenylalanyl-histidine replacements | MERCK & CO. INC. (US) | 1988-08-17 | — | — | EP | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-117865876-A | Method for preparing ramipril intermediate | 浙江华海药业股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-0326974-A1 | Amino acid amides with a psychotropic activity, processes for their preparation, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-09 | — | — | EP | disclosed |
| EP-0317878-A1 | Stabilized pharmaceutical agents, process for preparing them, and stable pharmaceutical preparations | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-31 | — | — | EP | disclosed |
| US-4816466-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-03-28 | — | — | US | disclosed |
| EP-0278158-A2 | Renin inhibitors containing phenylalanyl-histidine replacements | MERCK & CO. INC. (US) | 1988-08-17 | — | — | EP | disclosed |
| EP-0214570-A2 | N-alkylated tripeptides, process for their preparation, medicaments containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-03-18 | — | — | EP | disclosed |
| US-4525301-A | REACTING TRIFLUOROMETHANE SULFONIC ACID DERIVATIVES WITH AMINO ACID ESTERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143981-A1 | WHOLE-CELL CATALYTIC SYSTEM COMPRISING A HYDANTOINASE, A RACEMASE AND A CARBAMOYLASE | AHCY, NAAA, LAP3 | CYP2D6 435/4885LMNA 2234/4885BLM 2387/4885 |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CYP2D6 4444/4885LMNA 984/4885BLM 2823/4885 |
| US-20100286404-A1 | PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF | ACE, AGTR1, REN | CYP2D6 7/4885LMNA 2592/4885BLM 2153/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | CYP2D6 4444/4885LMNA 984/4885BLM 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.